MedPath

苏州欧康维视生物科技有限公司

Ownership
-
Established
2020-02-11
Employees
-
Market Cap
-
Website
https://www.ocumension.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

14

NMPA:14

Drug Approvals

Emedastine Difumarate Eye Drops

Product Name
富马酸依美斯汀滴眼液
Approval Number
国药准字H20258020
Approval Date
Feb 21, 2025
NMPA

Tafluprost Eye Drops

Product Name
他氟前列素滴眼液
Approval Number
国药准字H20253359
Approval Date
Feb 8, 2025
NMPA

Bromfenac Sodium Eye Drops

Product Name
溴芬酸钠滴眼液
Approval Number
国药准字H20253042
Approval Date
Jan 2, 2025
NMPA

Oxybuprocaine Hydrochloride Eye Drops

Product Name
盐酸奥布卡因滴眼液
Approval Number
国药准字H20249589
Approval Date
Dec 1, 2024
NMPA

Pranoprofen Eye Drops

Product Name
普拉洛芬滴眼液
Approval Number
国药准字H20249602
Approval Date
Dec 1, 2024
NMPA

Brimonidine Tartrate Eye Drops

Product Name
酒石酸溴莫尼定滴眼液
Approval Number
国药准字H20249123
Approval Date
Oct 22, 2024
NMPA

Levofloxacin Eye Drops

Product Name
左氧氟沙星滴眼液
Approval Number
国药准字H20249151
Approval Date
Oct 22, 2024
NMPA

Levofloxacin Eye Drops

Product Name
左氧氟沙星滴眼液
Approval Number
国药准字H20244928
Approval Date
Sep 19, 2024
NMPA

Cetirizine Hydrochloride Eye Drops

Product Name
盐酸西替利嗪滴眼液
Approval Number
国药准字H20244893
Approval Date
Sep 10, 2024
NMPA

Diquafosol Sodium Eye Drops

Product Name
地夸磷索钠滴眼液
Approval Number
国药准字H20244235
Approval Date
Jun 28, 2024
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.